Dyne Therapeutics, Inc.
DYN
$12.40
$0.161.31%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.01% | 32.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.09% | 46.83% | |||
| Operating Income | 8.09% | -46.83% | |||
| Income Before Tax | 7.81% | -49.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.81% | -49.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.81% | -49.19% | |||
| EBIT | 8.09% | -46.83% | |||
| EBITDA | 8.14% | -47.03% | |||
| EPS Basic | 8.81% | -36.82% | |||
| Normalized Basic EPS | 8.79% | -36.81% | |||
| EPS Diluted | 8.81% | -36.82% | |||
| Normalized Diluted EPS | 8.79% | -36.81% | |||
| Average Basic Shares Outstanding | 1.09% | 9.05% | |||
| Average Diluted Shares Outstanding | 1.09% | 9.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
